Precision Oncology through Circulating Tumor Cell (CTC) Harvesting
ANGLE plc is a pioneering liquid biopsy company headquartered in the United Kingdom, internationally recognized for its groundbreaking Parsortix® system – the first and only FDA cleared technology for harvesting intact circulating tumor cells (CTCs) from patient blood samples. This revolutionary platform is transforming cancer diagnostics, enabling non-invasive, repeatable, and real time monitoring of cancer progression, therapeutic response, and disease recurrence.
At the heart of ANGLE’s innovation is the Parsortix® Cell Separation System, which enables label-free, epitope-independent isolation of viable CTCs based on size and deformability. This patented microfluidic technology ensures gentle enrichment of rare tumor cells without relying on surface markers, preserving cell integrity for downstream molecular, genomic, and functional analysis.
Key features and applications include:
Early Detection & Monitoring: Enables real-time insight into tumor evolution and metastasis without invasive tissue biopsies.
Personalized Treatment Planning: Supports therapeutic decision-making by providing actionable molecular data from CTCs.
Liquid Biopsy-Based Research: Facilitates studies in drug resistance, cancer heterogeneity, immune response, and biomarker discovery.
Compatible with Downstream Analysis: Harvested CTCs can be used for PCR, NGS, FISH, immunostaining, culture, or single-cell omics analysis.
The Parsortix® system is particularly valuable in breast, prostate, ovarian, and head & neck cancers where tumor accessibility is limited and longitudinal monitoring is crucial. It provides clinicians and researchers with a minimally invasive tool to gain dynamic, cellular-level insight into the disease process.
In 2022, Parsortix® received FDA De Novo clearance for use in metastatic breast cancer, a major milestone that positions ANGLE as a key enabler of precision oncology and personalized cancer care.
With operations in the UK, USA, and Canada, and collaborations with leading cancer centers and pharmaceutical companies worldwide, ANGLE continues to advance its mission: to make liquid biopsy a routine component of cancer care and clinical research.
Partnering with ANGLE means accessing cutting edge liquid biopsy technology that empowers clinicians and researchers to redefine how cancer is understood, monitored, and treated.